Suninat 50 mg | Sunitinib | Blueberry pharmacologicals

SUNINAT 50MG
Suninat 50 mg Tablets Is A Type Of Targeted Therapy And Is A Receptor Protein-Tyrosine Kinase Inhibitor. It Prevents The Actions Of Vascular Endothelial Growth Factor (VEGF) And Is An Angiogenesis Inhibitor.
Suninat 50 mg Is A Prescription Drugs Which Is Used Under The guidance of medical practices.

INDICATION:
Suninat 50mg is used for the treatment of following conditions

• Gastrointestinal stromal tumor
• Advanced pancreatic neuroendocrine tumor
• Advanced renal cell cancer.

MECHANISM :
Sunitinib is performing to stop tumor cell development in several ways. Sunitinib aims several enzymes on blood vessel cells and cancer cells. Various of these targets are thought to be included in angiogenesis (making of blood vessels).

PRECAUTIONS :
Suninat 50mg treatment will causes severe hepatotoxicity involving liver failure; check liver function tests before starting treatment.

Haemorrhagic events involving tumor-related haemorrhageresulted; test the serial complete blood counts and physical examinations.

Adrenal haemorrhageoccurred in animal studies; check the adrenal function in case of stress such as surgery, trauma or severe infection Control urine protein; interfere with treatment for 24-hr urine protein ≥3 g; stop for repeat episodes of protein ≥3 g despite dose reductions or nephrotic syndrome

DOSAGE AND ADMINISTRATION :
The recommended dosage for following condition as follows :
Gastrointestinal Stromal Tumor :
Dose after disease progression on or intolerance to imatinib mesylate
The recommended dose is 50 mg PO qDay for 4 weeks, followed by 2 weeks drug-free, repeat cycle.
Renal Cell Carcinoma :
The recommended dose is 50 mg PO qDay for 4 weeks, followed by2 weeks drug-free, repeat cycle.
Adjuvant treatment of RCC :
• Used for the adjuvant therapy of adult patients at high risk of recurrent RCC following nephrectomy
• The recommended dose is 50 mg PO qDay for 4 weeks, followed by2 weeks drug-free, repeat cycle for a maximum of nine 6-week cycles totally
Pancreatic Neuroendocrine Tumor :
Required for progressive, well-differentiated pancreatic neuroendocrine tumor (pNET) in patients with unresectable locally advanced or metastatic disease
The recommended dose is 37.5 mg PO qDay continuously without

INTERACTION-DRUG:
. Concomitant Use Of CYP3A4 Inducers (Rifampin) Will Decrease Sunitinib Plasma Concentration
Concomitant Use With CYP3A4 Inhibitors (Ketoconazole0 Will Increase The Sunitinib Plasma Concentrations.
CONTRAINDICATIONS:
Patients Are Contraindicated With Suninat 50 mg Due To Hypersensitivity And Renal Impairment.

Advanance
women : there is no available data established by along risk in animal development and reproductive studies.
Advivese females of reproductive potential possible of the probable hazards to a foetus and use of effective contraception.

LACTATION:
. Decision Should Be Taken About Discontinue The Nursing Or To Stop The Drug Considering The Important Of The Drug To The Mother
Possible Of Severe Side Effects In Breastfed Infants From Sunitinib , Avoid Breast Feeding During Treatment.

FOR MORE INFORMATION:
Call us: + 91-97890 77748
Mail to: info@blueberrypharma.com
Domain: https://blueberrypharma.com/suninat-50mg.php